The 10-second takeaway
For the quarter ended June 30 (Q2), Amedisys missed estimates on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue dropped significantly. Non-GAAP earnings per share contracted significantly. GAAP earnings per share dropped significantly.
Gross margins increased, operating margins dropped, net margins shrank.
Amedisys recorded revenue of $313.1 million. The 11 analysts polled by S&P Capital IQ wanted to see revenue of $328.0 million on the same basis. GAAP reported sales were 16% lower than the prior-year quarter's $373.8 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.
EPS came in at $0.17. The 11 earnings estimates compiled by S&P Capital IQ predicted $0.10 per share. Non-GAAP EPS of $0.17 for Q2 were 37% lower than the prior-year quarter's $0.27 per share. GAAP EPS of $0.06 for Q2 were 77% lower than the prior-year quarter's $0.26 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.
For the quarter, gross margin was 43.8%, 60 basis points better than the prior-year quarter. Operating margin was 1.2%, 300 basis points worse than the prior-year quarter. Net margin was 0.6%, 150 basis points worse than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $325.5 million. On the bottom line, the average EPS estimate is $0.13.
Next year's average estimate for revenue is $1.32 billion. The average EPS estimate is $0.47.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 803 members out of 889 rating the stock outperform, and 86 members rating it underperform. Among 213 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 186 give Amedisys a green thumbs-up, and 27 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Amedisys is hold, with an average price target of $9.11.
Is Amedisys the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Amedisys to My Watchlist.